Recently, Meja et al. [55] demonstrated the synergistic cytotoxicity of a combination of AKT and PIM inhibitors in AML, with convergence on inhibition of Myc, MCL-1, and BAD. The gene discussed is MYC; the disease is acute myeloid leukemia.